PTO/SB/08s (08-03)
Approved for use through 97/31/2006, ONE 0851-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number		10538107	
	Filing Date		2005-06-08	
INFORMATION DISCLOSURE	First Named Inventor Chang		ngiong NING	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		2821	
not to outside of or K 1.33)	Examiner Name			
	Attorney Docket Numb	er	NL021254	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document		Releva		Lines where les or Relev	
	1	6307321	B1	2001-10	1-23	HONDA ET AL					
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Decument		Releva		Lines where	
	1	20020070668	A1	2002-06	i-13						
If you wisl	h to a	dd additional U.S. Publi						d button	=		
				FOREK	SN PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date			vhere Rele	or Relevant	т.
	1	1376655	EP		A2	2004-01-02	MATSUSHITA IND LTD	СО			
	2	1089322	EP		A1	2001-04-04	USHIODENKI KK				
	3	1134775	EP		A2	2001-09-19	USHIODENKI KK				

(Not for submission under 37 CFR 1.99)		991								
(Not for Submission diluci of Ofice 1.30)			Exam	Examiner Name						
			Atton	Attorney Docket Number			NL021254			
•										
	4	1134785		EP	A1	2001-09-19) NE	C CORP		
	5	1150336		EP	A2	2001-10-31	MA	ATSUSHITA IND CO		

MATSUSHITA IND CO

Examiner Initials*	No	(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

A1 2001-11-14 KTD

EXAMINER SIGNATURE

FP

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Nati Codes of USPTO Patent Documents at year USPTO_GOV or NEPP 041.04. 2 Enter office that issued the document, by the Noveletro (WIPO Standard STA). 3 For Upparence patent occument, by the Noveletro of the parent for the parent patent document. (* Nord of document by the appropriate symbols as indicated on the document of the appropriate symbols as indicated on the document of the USPTO Standard STA, 16 if possible. 3 Applicant is to place a check mark here if Empirical Instances and Common of the USPTO Standard STA, 16 if possible. 3 Applicant is to place a check mark here if Empirical Instances and Common of the USPTO Standard STA, 16 if possible. 3 Applicant is to place a check mark here if Empirical Instances and Common of the USPTO Standard STA, 16 if possible. 3 Applicant is to place a check mark here if Empirical Instances and Common of the USPTO Standard STA, 16 if possible. 3 Applicant is to place a check mark here if Empirical Instances and Instances an

6 1154463

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10538107		
Filing Date		2005-06-08		
First Named Inventor	Changiong NING			
Art Unit		2821		
Examiner Name				
Attorney Docket Number		NI 021254		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on the agradate.									
Signature	/Frank Keegan/	Date (YYYY-MM-DD)	2007-06-26						
Name/Print	Frank Keegan	Registration Number	50.145						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.